Bam R A, Hansen D, Irrinki A, Mulato A, Jones G S, Hesselgesser J, Frey C R, Cihlar T, Yant S R. 2017. TLR7 Agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells. Antimicrobial Agents and Chemotherapy, 61, 1369–1316.

Cheadle E J, Lipowska-Bhalla G, Dovedi S J, Fagnano E, Klein C, Honeychurch J, Illidge T M. 2017. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia, 31, 1611–1621.

Coleman L G J, Zou J, Crews F T. 2017. Microglial-derived miRNA let-7 and HMGB1 contribute to ethanol-induced neurotoxicity via TLR7. Journal of Neuroinflammation, 14, 22–33.

Das D, Sengupta I, Sarkar N, Pal A, Saha D, Bandopadhyay M, Das C, Narayan J, Singh S P, Chakrabarti S, Chakravarty R. 2017. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line. BMC Infectious Disease, 17, 76–87.

Enosi Tuipulotu D, Netzler N E, Lun J H, Mackenzie J M, White P A. 2018. TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation. Antimicrob Agents Chemother, 62, e02417–17.

Fernandes-Santos C, Azeredo E L. 2022. Innate immune response to dengue virus: Toll-like receptors and antiviral response. Viruses, 14, 992.

Fletcher S, Steffy K, Averett D. 2006. Masked oral prodrugs of toll-like receptor 7 agonists: A new approach for the treatment of infectious disease. Current Opinion in Investigational Drugs, 7, 702–708.

Gosu V, Basith S, Kwon O P, Choi S. 2012. Therapeutic applications of nucleic acids and their analogues in toll-like receptor signaling. Molecules, 17, 13503–13529.

Gotovtseva E P, Kapadia A S, Smolensky M H, Lairson D R. 2008. Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: A meta-analysis. Sexually Transmitted Diseases, 35, 346–351.

Guo Y K, Ming S L, Zeng L, Chang W R, Pan J J, Zhang C, Wan B, Wang J, Su Y, Yang G Y, Chu B B. 2021. Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity. Molecular Immunology, 136, 55–64.

Herschke F, Li C, Zhu R, Han Q, Wu Q, Lu Q, Barale-Thomas E, Jonghe S D, Lin T I, An D C. 2021. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms. Antiviral Research, 196, 105196.

Hu Y, Tang L, Zhu Z, Meng H, Chen T, Zhao S, Jin Z, Wang Z, Jin G. 2020. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model. Journal of Translational Medicine, 18, 112–125.

Inglefield J R, Dumitru C D, Alkan S S, Gibson S J, Lipson K E, Tomai M A, Larson C J, Vasilakos J P. 2008. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. Journal of Interferon Cytokine Research, 28, 253–263.

Jahanban-Esfahlan R, Seidi K, Majidinia M, Karimian A, Yousefi B, Nabavi S M, Astani A, Berindan-Neagoe I, Gulei D, Fallarino F, Gargaro M, Manni G, Pirro M, Xu S, Sadeghi M, Nabavi S F, Shirooie S. 2019. Toll-like receptors as novel therapeutic targets for herpes simplex virus infection. Reviews in Medical Virology, 29, e2048.

Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, Chlupac J, Chaperot L, Durand S, Baumert T F, Pichova I, Lubyova B, Hirsch I, Weber J. 2020. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Scientific Reports, 10, 12767.

Kanneganti T D, Ozoren N, Body-Malapel M, Amer A, Park J H, Franchi L, Whitfield J, Barchet W, Colonna M, Vandenabeele P, Bertin J, Coyle A, Grant E P, Akira S, Nunez G. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature, 440, 233–236.

Koerner J, Horvath D, Herrmann V L, MacKerracher A, Gander B, Yagita H, Rohayem J, Groettrup M. 2021. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nature Communications, 12, 2935.

Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, Michelet M, Floriot O, Ollivier A, Rivoire M, Ait-Goughoulte M, Daffis S, Fletcher S P, Salvetti A, Cosset F L, Zoulim F, Durantel D. 2018. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Scientific Reports, 8, 5390.

Mark K, Corey L, Meng T, Magaret A, Huang M, Selke S, Slade H, Tyring S, Warren T, Sacks S, Leone P, Bergland V, Wald A. 2007. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: A randomized, controlled trial. The Journal of Infectious Diseases, 195, 1324–1331.

McGowan D C, Herschke F, Pauwels F, Stoops B, Smyej I, Last S, Pieters S, Embrechts W, Khamlichi M D, Thone T, Van Schoubroeck B, Mostmans W, Wuyts D, Verstappen D, Scholliers A, De Pooter D, Dhuyvetter D, Borghys H, Tuefferd M, Arnoult E, et al. 2017. Identification and optimization of Pyrrolo[3,2-d]pyrimidine toll-like receptor 7 (TLR7) selective agonists for the treatment of hepatitis B.
Journal of Medical Chemistry, 60, 6137–6151.

Meng J J, Song Y, Fan W, Yang L, Xing J, Wang J, Chu B, Yang G, Wang M. 2022. Effect of Toll-like Receptor 7 gene knockout on pmliferation of vesicular stomatitis virus. China Animal Husbandry & Veterinary Medicine, 49, 2011–2021. (in Chinese)

Menne S, Tumas D B, Liu K H, Thampi L, AlDeghaither D, Baldwin B H, Bellezza C A, Cote P J, Zheng J, Halcomb R, Fosdick A, Fletcher S P, Daffis S, Li L, Yue P, Wolfgang G H, Tennant B C. 2015. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.
Journal of Hepatology, 62, 1237–1245.

Mentrup T, Stumpff-Niggemann A Y, Leinung N, Schlosser C, Schubert K, Wehner R, Tunger A, Schatz V, Neubert P, Gradtke A C, Wolf J, Rose-John S, Saftig P, Dalpke A, Jantsch J, Schmitz M, Fluhrer R, Jacobsen I D, Schroder B. 2022. Phagosomal signalling of the C-type lectin receptor Dectin-1 is terminated by intramembrane proteolysis. Nature Communications, 13, 1880.

Miller R, Gerster J, Owens M, Slade H, Tomai M. 1999. Imiquimod applied topically: A novel immune response modifier and new class of drug. International Journal of Immunopharmacology, 21, 1–14.

Naqvi I, Giroux N, Olson L, Morrison S A, Llanga T, Akinade T O, Zhu Y, Zhong Y, Bose S, Arvai S, Abramson K, Chen L, Que L, Kraft B, Shen X, Lee J, Leong K W, Nair S K, Sullenger B. 2022. DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists. Biomaterials, 283, 121393.

Nishii N, Tachinami H, Kondo Y, Xia Y, Kashima Y, Ohno T, Nagai S, Li L, Lau W, Harada H, Azuma M. 2018. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. Oncotarget, 9, 13301–13312.

Savidis G, McDougall W M, Meraner P, Perreira J M, Portmann J M, Trincucci G, John S P, Aker A M, Renzette N, Robbins D R, Guo Z, Green S, Kowalik T F, Brass A L. 2016. Identification of zika virus and dengue virus dependency factors using functional genomics. Cell Reports, 16, 232–246.

Shao Y, Saredy J, Yang W Y, Sun Y, Lu Y, Saaoud F, Drummer C T, Johnson C, Xu K, Jiang X, Wang H, Yang X. 2020. Vascular endothelial cells and innate immunity. Arteriosclerosis Thrombiosis and Vasculae Biology, 40, e138–e152.

Song R, Gao Y, Dozmorov I, Malladi V, Saha I, McDaniel M M, Parameswaran S, Liang C, Arana C, Zhang B, Wakeland B, Zhou J, Weirauch M T, Kottyan L C, Wakeland E K, Pasare C. 2021. IRF1 governs the differential interferon-stimulated gene responses in human monocytes and macrophages by regulating chromatin accessibility. Cell Reports, 34, 108891.

Song Y, Fan W, Yao C, Wang H, Lu X, Wang Y, Liu P, Ma Y, Zhang Z, Wang J, Chu B, Shi L, Yang G, Wang M. 2024. Design, synthesis and biological evaluation of quinazoline and pyrrolo[3,2-d]pyrimidine derivatives as TLR7 agonists for antiviral agents. Organic & Biomolecular Chemistry, 22, 2764–2773.

Takeda K, Akira S. 2004. TLR signaling pathways. Seminars in Immunology, 16, 3–9.

Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, Parkinson T. 2007. Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrobial Agents and Chemotherapy, 51, 2969–2978.

Tomai M, Miller R, Lipson K, Kieper W, Zarraga I, Vasilakos J. 2007. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Review of Vaccines, 6, 835–847.

Vanwalscappel B, Tada T, Landau N R. 2018. Toll-like receptor agonist R848 blocks Zika virus replication by inducing the antiviral protein viperin. Virology, 522, 199–208.

Wang J, Li G L, Ming S L, Wang C F, Shi L J, Su B Q, Wu H T, Zeng L, Han Y Q, Liu Z H, Jiang D W, Du Y K, Li X D, Zhang G P, Yang G Y, Chu B B. 2020. BRD4 inhibition exerts anti-viral activity through DNA damage-dependent innate immune responses. PLoS Pathogen, 16, e1008429.

Wang Q, Zhou L, Wang J, Su D, Li D, Du Y, Yang G, Zhang G, Chu B.
2022. African swine fever virus K205R induces ER stress and consequently activates autophagy and the NF-κB signaling pathway. Viruses, 14, 394.

Wang X, Yu B, Cao B, Zhou J, Deng Y, Wang Z, Jin G. 2021. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation. International Journal of Cancer, 148, 437–447.

Xiao L, Liu Y, Wang N. 2014. New paradigms in inflammatory signaling in vascular endothelial cells. American Journal of Physiology Heart and Circulatory Physiology, 306, 317–325.

Xun Y, Yang H, Kaminska B, You H. 2021. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma. Journal of Hematology & Oncology, 14, 176–207.

Ye C, Huang Q, Jiang J, Li G, Xu D, Zeng Z, Peng L, Peng Y, Fang R. 2021. ATP-dependent activation of NLRP3 inflammasome in primary murine macrophages infected by pseudorabies virus. Veterinary Microbiology, 259, 109130.

Yeh F, Chen C, Xie C, Baxan N, Zhao L, Ashek A, Sabrin F, Lawrie A, Wilkins M, Zhao L. 2023. TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension. The European Respiratory Journal, 62, 2300204.

Zhang Z, Ohto U, Shibata T, Krayukhina E, Taoka M, Yamauchi Y, Tanji H, Isobe T, Uchiyama S, Miyake K, Shimizu T. 2016. Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. Immunity, 45, 737–748.

Zhou Q, Zhang L, Lin Q, Liu H, Ye G, Liu X, Jiao S, Li J, Tang Y, Shi D, Huang L, Weng C. 2023. Pseudorabies virus infection activates the TLR-NF-κB axis and AIM2 inflammasome to enhance inflammatory responses in mice. Journal of Virology, 97, e0000323.